• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by BeiGene Ltd. (Amendment)

    5/5/23 4:33:08 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGNE alert in real time by email
    SC 13D/A 1 tm2314788d1_sc13da.htm SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

    TO RULE 13d-2(a)

     

    (Amendment No. 9)*

     

    BeiGene, Ltd.

    (Name of Issuer)
         

    Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)
         
     

    07725L102**

     
      (CUSIP number)  
         

    Alexandra A. Toohey

    Chief Financial Officer

    Baker Bros. Advisors LP

    860 Washington Street, 3rd Floor

    New York, NY 10014

    (212) 339-5690

     

    (Name, address and telephone number of person authorized to receive notices and communications)
         
      May 3, 2023  
      (Date of event which requires filing of this statement)  
         

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    (Continued on the following pages)

     

    (Page 1 of 10 Pages)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

    **This CUSIP applies to the American Depositary Shares, each representing thirteen Ordinary Shares

     

     

     

     

      

    CUSIP No. 07725L102   Page 2 of 9 Pages

     

    1.

    NAMES OF REPORTING PERSONS

    Baker Bros. Advisors LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

    3. SEC USE ONLY
    4.

    SOURCE OF FUNDS*

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ¨
    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    7. SOLE VOTING POWER: 152,522,377 (1)
    8. SHARED VOTING POWER: 0
    9. SOLE DISPOSITIVE POWER: 152,522,377 (1)
    10. SHARED DISPOSITIVE POWER: 0

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    152,522,377 (1)

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    11.2% (1)(2)

    14.

    TYPE OF REPORTING PERSON*

    IA, PN

    (1) Includes 151,695,661 of the Ordinary Shares (“Ordinary Shares”) of BeiGene, Ltd. (the “Issuer”) reported that are beneficially owned through American Depositary Shares (“ADS”), 34,164 Ordinary Shares received from vested restricted stock units of the Issuer, 33,384 Ordinary Shares underlying 33,384 restricted stock units solely payable in Ordinary Shares (each, an “RSU”) vesting in 60 days and 759,122 Ordinary Shares underlying 759,122 options to purchase Ordinary Shares (“Share Options”). Each ADS represents 13 Ordinary Shares of the Issuer.

    (2) Based on 1,359,052,003 Ordinary Shares outstanding at April 30, 2023 as reported by the Issuer on the Hong Kong Exchange and Clearing Limited (“HKEX”) on May 3, 2023.

     

     

     

     

    CUSIP No. 07725L102   Page 3 of 9 Pages

     

    1.

    NAMES OF REPORTING PERSONS

    Baker Bros. Advisors (GP) LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

    3. SEC USE ONLY
    4.

    SOURCE OF FUNDS*

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ¨
    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    7. SOLE VOTING POWER: 152,522,377 (1)
    8. SHARED VOTING POWER: 0
    9. SOLE DISPOSITIVE POWER: 152,522,377 (1)
    10. SHARED DISPOSITIVE POWER: 0

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    152,522,377 (1)

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    11.2% (1)(2)

    14.

    TYPE OF REPORTING PERSON*

    HC, OO

    (1) Includes 151,695,661 of the Ordinary Shares the Issuer reported that are beneficially owned through ADS, 34,164 Ordinary Shares received from vested RSUs, 33,384 Ordinary Shares underlying 33,384 RSUs vesting in 60 days and 759,122 Ordinary Shares underlying 759,122 Share Options. Each ADS represents 13 Ordinary Shares of the Issuer.

    (2) Based on 1,359,052,003 Ordinary Shares outstanding at April 30, 2023 as reported by the Issuer on the HKEX on May 3, 2023.

     

     

     

     

    CUSIP No 07725L102   Page 4 of 9 Pages

      

    1.

    NAMES OF REPORTING PERSONS

    Felix J. Baker

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

    3. SEC USE ONLY
    4.

    SOURCE OF FUNDS*

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ¨
    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    7. SOLE VOTING POWER: 152,978,037 (1)
    8. SHARED VOTING POWER:
    9. SOLE DISPOSITIVE POWER: 152,978,037 (1)
    10. SHARED DISPOSITIVE POWER:

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    152,978,037 (1)

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    11.2% (1)(2)

    14.

    TYPE OF REPORTING PERSON*

    IN, HC

    (1) Includes 152,151,311 of the Ordinary Shares the Issuer reported that are beneficially owned through ADS, 34,164 Ordinary Shares received from vested RSUs, 33,384 Ordinary Shares underlying 33,384 RSUs vesting in 60 days and 759,122 Ordinary Shares underlying 759,122 Share Options. Each ADS represents 13 Ordinary Shares of the Issuer.

    (2) Based on 1,359,052,003 Ordinary Shares outstanding at April 30, 2023 as reported by the Issuer on the HKEX on May 3, 2023.

     

     

     

     

    CUSIP No. 07725L102   Page 5 of 9 Pages

       

    1.

    NAMES OF REPORTING PERSONS

    Julian C. Baker

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) ¨

    3. SEC USE ONLY
    4.

    SOURCE OF FUNDS*

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ¨
    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    7. SOLE VOTING POWER: 152,978,037 (1)
    8. SHARED VOTING POWER
    9. SOLE DISPOSITIVE POWER: 152,978,037 (1)
    10. SHARED DISPOSITIVE POWER:

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    152,978,037 (1)

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    11.2% (1)(2)

    14.

    TYPE OF REPORTING PERSON*

    IN, HC

    (1) Includes 152,151,311 of the Ordinary Shares the Issuer reported that are beneficially owned through ADS, 34,164 Ordinary Shares received from vested RSUs, 33,384 Ordinary Shares underlying 33,384 RSUs vesting in 60 days and 759,122 Ordinary Shares underlying 759,122 Share Options. Each ADS represents 13 Ordinary Shares of the Issuer.

    (2) Based on 1,359,052,003 Ordinary Shares outstanding at April 30, 2023 as reported by the Issuer on the HKEX on May 3, 2023.

     

     

     

     

    CUSIP No. 07725L102   Page 6 of 9 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

     FBB3 LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a)

    (b)

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

     OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    144,517 (1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    144,517 (1)

    10

    SHARED DISPOSITIVE POWER

     

    0

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    144,517 (1)

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    (2)

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    OO

        

    (1)Includes 144,508 Ordinary Shares reported that are beneficially owned through ADS.
    (2)The percentage is less than 0.1% based on 1,359,052,003 Ordinary Shares outstanding at April 30, 2023 as reported by the Issuer on the HKEX on May 3, 2023.

     

     

     

     

    Amendment No. 9 to Schedule 13D

     

    This Amendment No.9 to Schedule 13D amends and supplements the previously filed Schedules 13D filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP), LLC (the “Adviser GP”), Julian C. Baker, Felix J. Baker and FBB3 LLC (“FBB3”) (collectively the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    The Adviser GP is the sole general partner of the Adviser. Pursuant to the management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”), and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power over securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of this Schedule 13D is hereby amended and restated as follows:

     

    (a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 9 are incorporated herein by reference.

     

    Set forth below is the aggregate number of Ordinary Shares of BeiGene, Ltd. (the “Issuer”) directly held by the Funds, 151,695,661 of which are directly held by the Funds through American Depositary Shares (“ADS”), along with the percentage of the Issuer’s outstanding Ordinary Shares such holdings represent. The information set forth below is based on 1,359,052,003 Ordinary Shares outstanding at April 30, 2023 as reported by the Issuer on the Hong Kong Exchange and Clearing Limited (“HKEX”) on May 3, 2023. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

     

    Name  Number of Ordinary Shares we own or have the right to acquire within 60 days   Percent of Class Outstanding 
    667, L.P.   12,596,280    0.9%
    Baker Brothers Life Sciences, L.P.   139,099,427    10.3%
    Total   151,695,707    11.2%

     

    Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, have served on the board of directors of the Issuer (the “Board”) since April 21, 2015 and October 7, 2014, respectively. Prior to serving on the Board, Michael Goller was a Board observer. Michael Goller and Ranjeev Krishana currently serve on the Board as representatives of the Funds. Michael Goller and Ranjeev Krishana each hold 379,561 options to purchase Ordinary Shares (“Share Options”) received in connection with their service on the Board which are exercisable within 60 days from the date of this Amendment No. 9. Michael Goller and Ranjeev Krishana each hold 17,082 Ordinary Shares which were received upon the vesting of restricted stock units (“RSUs”) in connection with their service on the Board. Michael Goller and Ranjeev Krishana each hold 16,692 RSUs which were received in connection with their service on the Board and which vest within 60 days of the date of this Amendment No. 9. The policy of the Funds and the Adviser does not permit managing members of the Adviser GP or full-time employees of the Adviser to receive compensation for serving as directors of the Issuer, and the Funds are instead entitled to the pecuniary interest in any compensation received for their service.

     

     

     

     

    The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

     

    Julian C. Baker and Felix J. Baker are also the sole managers of FBB3 and by policy they do not transact in or vote the securities of the Issuer held by FBB3.

     

    (c) None of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days.

     

    (d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the managing members of Baker Biotech Capital (GP), LLC.

     

    Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the managing members of Baker Brothers Life Sciences Capital (GP), LLC.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

       

    Item 6 of Schedule 13D is supplemented and amended, as the case may be, as follows:

     

    On May 3, 2023, the Issuer and the Funds along with 14159, L.P., Hillhouse BGN Holdings Limited, HHLR Fund L.P., and YHG Investment L.P. entered into Amendment No. 2 (the “Second Amendment”) to the Registration Rights Agreement that was previously disclosed and entered into on November 16, 2016 and subsequently amended on December 1, 2020. Pursuant to the Second Amendment, the Issuer’s registration obligations under the Registration Rights Agreement will continue in effect for up to another three years, until December 31, 2026, unless otherwise terminated pursuant to the Registration Rights Agreement, as amended. Other than such modification the terms and conditions of the Registration Rights Agreement remain in full force and effect.

     

    The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment, which is incorporated by reference as Exhibit 99.1 hereto and is incorporated herein by reference.

     

    Item 7. Materials to be filed as Exhibits

     

    Exhibit Description
    99.1 Amendment No. 2 to Registration Rights Agreement, dated May 3, 2023, by and among the Issuer, the Funds, 14159, L.P., Hillhouse BGN Holdings Limited, HHLR Fund, L.P. and YHG Investment, L.P. (incorporated by reference to Exhibit 10.3 to the Issuer’s Current Report on Form 8-K, filed with the SEC on May 4, 2023).

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    May 5, 2023

     

     

    BAKER BROS. ADVISORS LP

     

    By: Baker Bros. Advisors (GP) LLC, its general partner

         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      /s/ Julian C. Baker
      Julian C. Baker
       
      /s/ Felix J. Baker
      Felix J. Baker
       
      FBB3 LLC
     

     

    /s/ Julian C. Baker
        Name: Julian C. Baker
        Title: Manager

     

     

     

     

     

    Get the next $BGNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGNE

    DatePrice TargetRatingAnalyst
    12/3/2024$300.00Overweight
    Morgan Stanley
    9/18/2024$288.00Mkt Outperform
    JMP Securities
    2/6/2024$185.00Overweight
    JP Morgan
    9/12/2023$259.00Outperform
    Macquarie
    8/17/2023$287.00Buy
    Jefferies
    7/17/2023$275.00Buy
    Citigroup
    6/30/2023$335.00 → $196.00Outperform → Mkt Perform
    Bernstein
    1/12/2023$308.00Buy
    Daiwa Securities
    More analyst ratings

    $BGNE
    SEC Filings

    See more
    • BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      12/23/24 6:05:32 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      12/10/24 6:02:43 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BeiGene Ltd.

      144 - BeiGene, Ltd. (0001651308) (Subject)

      12/9/24 9:48:25 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

      Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with chemotherapy BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lu

      3/31/25 6:00:00 AM ET
      $BGNE
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

      New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors e

      12/27/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. "As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative h

      12/23/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Oyler John exercised 1,300,000 units of Ordinary Shares at a strike of $0.50, increasing direct ownership by 77% to 2,978,833 units (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/17/24 5:02:43 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chair, Scientific Advisory Brd Wang Xiaodong sold $7,805,106 worth of American Depositary Shares (41,760 units at $186.90) and exercised 41,760 units of American Depositary Shares at a strike of $6.50 (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/12/24 5:18:09 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Bros. Advisors Lp sold $194,200,043 worth of American Depositary Shares (1,037,017 units at $187.27) (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/10/24 9:25:48 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

      12/10/24 9:30:34 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

      12/4/24 4:05:33 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Filed by)

      10/31/24 6:29:37 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Financials

    Live finance-specific insights

    See more
    • BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors

      BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. "With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynam

      7/10/23 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

       Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic

      12/13/22 10:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research on August 25, 2021

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company's early development pipeline and research. A live webcast of the conference call can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days. About BeiGene BeiGene is a global, science-driven biotechnology company

      8/16/21 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board's Audit Committee, effective September 27, 2024. "We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. "The Board is looking forward to collaborating with Shalini, whose extensive experience in leading innovative global pharmaceutical companies will be invaluable as we enter new markets, advance our pipeline of groundbreaking cancer therapies, and embark on a transformative growth phase. Her financial

      9/26/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Announces Updates to Commercial Leadership Team

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov

      9/9/24 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on BeiGene with a new price target

      Morgan Stanley resumed coverage of BeiGene with a rating of Overweight and set a new price target of $300.00

      12/3/24 8:35:59 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on BeiGene with a new price target

      JMP Securities initiated coverage of BeiGene with a rating of Mkt Outperform and set a new price target of $288.00

      9/18/24 7:31:13 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan resumed coverage on BeiGene with a new price target

      JP Morgan resumed coverage of BeiGene with a rating of Overweight and set a new price target of $185.00

      2/6/24 7:59:18 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care